Invion Limited (FRA:7C8)

Market Cap	3.91M
Revenue (ttm)	n/a
Net Income (ttm)	-4.92M
Shares Out	n/a
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	2
Open	0.0295
Previous Close	0.0300
Day's Range	0.0295 - 0.0295
52-Week Range	0.0295 - 0.2500
Beta	n/a
RSI	43.57
Earnings Date	Nov 27, 2025

About Invion

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7C8

Financial Performance

Financial numbers in AUD